JP6257787B2 - Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物 - Google Patents

Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物 Download PDF

Info

Publication number
JP6257787B2
JP6257787B2 JP2016549753A JP2016549753A JP6257787B2 JP 6257787 B2 JP6257787 B2 JP 6257787B2 JP 2016549753 A JP2016549753 A JP 2016549753A JP 2016549753 A JP2016549753 A JP 2016549753A JP 6257787 B2 JP6257787 B2 JP 6257787B2
Authority
JP
Japan
Prior art keywords
compound
group
mmol
pharmaceutical composition
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505319A (ja
Inventor
チャン、ダウェイ
Original Assignee
チャンスー メドリューション リミテッド
チャンスー メドリューション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チャンスー メドリューション リミテッド, チャンスー メドリューション リミテッド filed Critical チャンスー メドリューション リミテッド
Publication of JP2017505319A publication Critical patent/JP2017505319A/ja
Application granted granted Critical
Publication of JP6257787B2 publication Critical patent/JP6257787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016549753A 2014-02-04 2015-02-03 Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物 Active JP6257787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461965584P 2014-02-04 2014-02-04
US61/965,584 2014-02-04
PCT/CN2015/072179 WO2015117547A1 (en) 2014-02-04 2015-02-03 Substituted pyrimidines useful as egfr-t790m kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017505319A JP2017505319A (ja) 2017-02-16
JP6257787B2 true JP6257787B2 (ja) 2018-01-10

Family

ID=53777338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549753A Active JP6257787B2 (ja) 2014-02-04 2015-02-03 Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物

Country Status (8)

Country Link
US (1) US10167264B2 (enExample)
EP (1) EP3102571B1 (enExample)
JP (1) JP6257787B2 (enExample)
CN (1) CN105980377B (enExample)
DK (1) DK3102571T3 (enExample)
ES (1) ES2667847T3 (enExample)
NO (1) NO2718543T3 (enExample)
WO (1) WO2015117547A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554347B (zh) * 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
CN106554318A (zh) * 2015-09-25 2017-04-05 正大天晴药业集团股份有限公司 氘代二苯基氨基嘧啶化合物
CN105461640B (zh) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法
CN106146406A (zh) * 2016-02-23 2016-11-23 深圳市塔吉瑞生物医药有限公司 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107344925B (zh) * 2016-05-04 2022-11-11 正大天晴药业集团股份有限公司 氘代二苯基氨基-三氟甲基嘧啶化合物
CN107088196A (zh) * 2017-02-27 2017-08-25 王涛 一种治疗骨质疏松症的药物组合物
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020257385A1 (en) 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
CA2861010A1 (en) * 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
ES2880109T3 (es) * 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩

Also Published As

Publication number Publication date
ES2667847T3 (es) 2018-05-14
US20170008856A1 (en) 2017-01-12
NO2718543T3 (enExample) 2018-01-06
DK3102571T3 (en) 2018-05-07
WO2015117547A1 (en) 2015-08-13
US10167264B2 (en) 2019-01-01
EP3102571A1 (en) 2016-12-14
CN105980377A (zh) 2016-09-28
EP3102571A4 (en) 2016-12-14
EP3102571B1 (en) 2018-04-04
JP2017505319A (ja) 2017-02-16
CN105980377B (zh) 2018-07-03

Similar Documents

Publication Publication Date Title
CN105980377B (zh) 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物
JP6871275B2 (ja) 新規アンモニウム誘導体、それを調製するためのプロセス及びそれを含有する医薬組成物
KR101335746B1 (ko) 이치환된 프탈라진 헷지호그 경로 길항제
JPWO2018143315A1 (ja) キナゾリン化合物
KR101562347B1 (ko) 시아노퀴놀린 유도체
JP6518690B2 (ja) （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン
JP2014521613A (ja) キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
KR20190086442A (ko) 피리딘 화합물
WO2013173254A1 (en) Bicyclic compounds as kinases inhibitors
WO2009125597A1 (ja) アシルチオウレア化合物又はその塩、及びその用途
US12338251B2 (en) Substituted macrocycles useful as kinase inhibitors
KR20150005698A (ko) 키나제 저해제로서 유용한 치환된 아미노퀴나졸린
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
JP6609308B2 (ja) キナーゼ阻害剤としての置換マクロサイクル
JP2012521970A (ja) Ｍｐｓ１キナーゼ阻害剤としてのｎ−アリール−２−（２−アリールアミノピリミジン−４−イル）ピロール−４−カルボキサミド誘導体
WO2016026423A1 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
JP7036332B2 (ja) キノリン又はキナゾリン化合物及びその応用
CA3151776A1 (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
AU2020410900B2 (en) Compound used as RET kinase inhibitor and application thereof
KR20190122764A (ko) 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제
Cao et al. Beyond acrylamide: a structure-guided investigation of covalent warheads in the development of CDK7 inhibitors
KR20150037207A (ko) Fms 키나아제 저해 활성을 갖는 피리미딘 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171205

R150 Certificate of patent or registration of utility model

Ref document number: 6257787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250